Two Sigma Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Two Sigma Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150,000	Closed	-$4.68M	–	1926
2025 Q4	$4.68M	Sell	150,000 -37,400	-20%	-$921K	0.01%	843
2025 Q3	$3.79M	Sell	187,400 -44,700	-19%	-$785K	0.01%	850
2025 Q2	$3.89M	Sell	232,100 -99,400	-30%	-$1.6M	0.01%	833
2025 Q1	$5.1M	Sell	331,500 -1,299,100	-80%	-$23.2M	0.01%	784
2024 Q4	$35.9M	Buy	1,630,600 +596,100	+58%	+$10.8M	0.08%	208
2024 Q3	$18.6M	Buy	1,034,500 +137,000	+15%	+$2.4M	0.04%	334
2024 Q2	$14.6M	Sell	897,500 -50,000	-5%	-$770K	0.03%	427
2024 Q1	$13.4M	Sell	947,500 -66,800	-7%	-$842K	0.03%	440
2023 Q4	$10.6M	Sell	1,014,300 -28,900	-3%	-$270K	0.02%	509
2023 Q3	$10.6M	Sell	1,043,200 -230,600	-18%	-$2.15M	0.03%	451
2023 Q2	$9.59M	Sell	1,273,800 -176,200	-12%	-$1.43M	0.02%	503
2023 Q1	$12.8M	Sell	1,450,000 -1,110,500	-43%	-$11M	0.03%	464
2022 Q4	$23.4M	Sell	2,560,500 -139,800	-5%	-$1.22M	0.07%	296
2022 Q3	$21.8M	Buy	2,700,300 +1,344,100	+99%	+$11.9M	0.06%	302
2022 Q2	$10.2M	Sell	1,356,200 -102,600	-7%	-$894K	0.03%	498
2022 Q1	$13.7M	Buy	1,458,800 +92,300	+7%	+$770K	0.04%	411
2021 Q4	$10.9M	Buy	1,366,500 +1,134,600	+489%	+$10.2M	0.03%	481
2021 Q3	$2.26M	Buy	+231,900	New	+$2.17M	0.01%	1184
2021 Q2	–	Sell	-333,200	Closed	-$3.85M	–	2691
2021 Q1	$3.85M	Sell	333,200 -163,900	-33%	-$1.88M	0.01%	964
2020 Q4	$4.8M	Sell	497,100 -244,000	-33%	-$2.34M	0.01%	837
2020 Q3	$6.68M	Sell	741,100 -278,500	-27%	-$2.95M	0.02%	664
2020 Q2	$12.6M	Sell	1,019,600 -1,039,100	-50%	-$11.8M	0.04%	470
2020 Q1	$18.5M	Buy	2,058,700 +904,800	+78%	+$9.27M	0.07%	309
2019 Q4	$11.3M	Buy	+1,153,900	New	+$10.3M	0.03%	560
2019 Q2	–	Sell	-194,399	Closed	-$3.05M	–	2432
2019 Q1	$3.05M	Buy	194,399 +22,599	+13%	+$399K	0.01%	1035
2018 Q4	$2.65M	Sell	171,800 -193,299	-53%	-$3.96M	0.01%	1051
2018 Q3	$7.86M	Sell	365,099 -3,002,500	-89%	-$69.7M	0.02%	657
2018 Q2	$81.9M	Sell	3,367,599 -503,400	-13%	-$10.3M	0.22%	120
2018 Q1	$66.2M	Sell	3,870,999 -2,381,600	-38%	-$46.5M	0.18%	154
2017 Q4	$118M	Buy	+6,252,599	New	+$94.1M	0.32%	80
2017 Q3	–	Sell	-121,499	Closed	-$4.04M	–	2348
2017 Q2	$4.04M	Sell	121,499 -4,482,200	-97%	-$139M	0.01%	845
2017 Q1	$148M	Buy	4,603,699 +837,100	+22%	+$28.6M	0.48%	32
2016 Q4	$137M	Buy	3,766,599 +2,849,900	+311%	+$114M	0.52%	37
2016 Q3	$42.2M	Sell	916,699 -1,450,900	-61%	-$75.7M	0.18%	132
2016 Q2	$119M	Buy	2,367,599 +882,100	+59%	+$47M	0.6%	31
2016 Q1	$79.5M	Buy	1,485,499 +1,354,200	+1,031%	+$79.5M	0.44%	53
2015 Q4	$8.62M	Sell	131,299 -1,215,100	-90%	-$75.1M	0.05%	347
2015 Q3	$76M	Sell	1,346,399 -64,801	-5%	-$4.2M	0.48%	55
2015 Q2	$83.4M	Buy	1,411,200 +2,500	+0.2%	+$154K	0.62%	21
2015 Q1	$87.8M	Buy	1,408,700 +1,072,600	+319%	+$62.4M	0.65%	19
2014 Q4	$19.3M	Buy	336,100 +57,900	+21%	+$3.23M	0.15%	174
2014 Q3	$15M	Buy	278,200 +259,140	+1,360%	+$13.7M	0.11%	216
2014 Q2	$999K	Buy	+19,060	New	+$974K	0.01%	1192
2014 Q1	–	Sell	-42,300	Closed	-$1.7M	–	2528
2013 Q4	$1.7M	Buy	+42,300	New	+$1.67M	0.02%	830
2013 Q3	–	Sell	-88,200	Closed	-$3.46M	–	2379
2013 Q2	$3.46M	Buy	+88,200	New	+$3.43M	0.05%	332

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's TEVA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 150,000 shares — an estimated $4.68M sold.

Two Sigma Advisers first reported a position in TEVA in Q2 2013 and held it in 45 quarters. The position peaked at $148M in Q1 2017. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Two Sigma Advisers reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 150,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $4.68M.
Two Sigma Advisers first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 45 quarters.
Two Sigma Advisers's Teva Pharmaceuticals position peaked at $148M in Q1 2017.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.